Data on Amgen
Bookmark
ShareAmgen is a company. It is in Thousand Oaks, the United States and it has a male CEO called Robert A. Bradway. It was founded in 1980 and is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Thousand Oaks
- environmental score (ESG): Try Pro to see estimate
- ESG score: Try Pro to see estimate
- CEO gender: male
- CEO: Robert A. Bradway
- foundation year: 1980
- social score (ESG): Try Pro to see estimate
- industry: Pharmaceuticals
- sector: Health Care
- revenues: 26.3B $
- employees: 24,200 people
- country: United States
- state: CA
- governance score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about Data on Amgen:
Dataset of stocks from Amgen:
Amgen is one of the companies in the United States, companies in Pharmaceuticals, companies in Health Care, companies in Robert A. Bradway, companies in Thousand Oaks and 3,584,319 companies in our database.
Talking Points
- AmgenA Worldwide Pioneer in Biotechnology
- Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
- Patients. They're why we develop and manufacture innovative human therapeutics to treat serious diseases. Community Guidelines: https://t.co/YlIOJSHFPG
- #WeareBiotech | Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
